| CASE REPORT |
|
| Year : 2023 | Volume
: 3
| Issue : 2 | Page : 433-435 |
|
|
Response of a single-dose intravitreal brolucizumab in type 3 macular neovascularization
Somnath Chakraborty1, Jay Umed Sheth2
1 Department of Vitreoretinal Services, Retina Institute of Bengal, Pradhan Nagar, Siliguri, West Bengal, India
2 Shantilal Shanghvi Eye Institute, Mumbai, Maharashtra, India
Correspondence Address:
Somnath Chakraborty
Retina Institute of Bengal, Pradhan Nagar, Siliguri - 734 003, West Bengal
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/IJO.IJO_2957_22
|
|
|
The authors describe a case of an 82-year-old female with type 3 macular neovascularization (MNV) who underwent a single-dose of intravitreal injection (IVI) of brolucizumab at baseline. The patient demonstrated significant visual improvement from 20/400 at baseline to 20/32 at 3 months without any significant adverse events. Notably, there was complete resolution of the subretinal fluid (SRF), intraretinal fluid (IRF), and subretinal hyperreflective material (SHRM) at 1 month postinjection, which was maintained for up to 3 months. Further prospective studies with a larger sample size are warranted to better understand the morphological and visual responses of type 3 MNV to brolucizumab therapy.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
